Acute Myeloid Leukemia

Acute Myeloid Leukemia

Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed.

Journal of Hematology & Oncology

IDH1 mutation limits the flexibility for citrate utilization in the presence of impaired complex I activity to a degree that is not apparent in IDH2 mutant cells, exposing a mutation-specific...

Nature Communications

Here, we first tested a novel oxime-containing derivative of 2-((2,4,5-trifluorobenzyl)oxy)benzaldehyde oxime (TFOBO) to evaluate its anticancer effect in myeloid leukemic cells.

Scientific Reports

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer...

Medical Xpress

We performed a retrospective analysis of 87 newly diagnosed FLT3 mutated AML patients treated on triplet (LIC + FLT3 inhibitor + Venetoclax, [N = 27]) and doublet...

Blood Cancer Journal

Montesinos et al found that the addition of ivosidenib to azacitidine in induction therapy significantly prolonged event-free survival in patients with newly diagnosed IDH1-mutated AML.

The ASCO Post

Massachusetts General Hospital (MGH) researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy...

Medical Xpress

In this study, we reported that Triptolide synergized with MDM2 inhibitor Nutlin-3a to suppress cell proliferation and induce mitochondrial-mediated apoptosis...

Experimental Hematology & Oncology

We used cross-sectional secondary data analyses to describe coping in 160 patients with newly diagnosed high-risk AML. 

Blood Advances

Our study aims to explore the cell differentiation effect of a potent histone deacetylase inhibitor (HDACi), I13, and its possible mechanism on AML cell lines.

Frontiers in Oncology

Pollard et al found that the addition of sorafenib to standard chemotherapy may benefit pediatric patients with high allelic ratio FLT3-ITD–positive acute myeloid leukemia (AML).

The ASCO Post

The purpose of this research is to identify the key lncRNAs and explore their functions in CN-AML by reconstructing the lncRNA–miRNA–mRNA network based on the...

Scientific Reports

IDH2 expression in AML cell lines and patient samples was evaluated by RT-qPCR, western blotting and database analyses. 

Journal of Hematology & Oncology

In this study, we hypothesized that presence of IDH1 c.315C>T SNP does not impact clinical outcome of AML patients because of the lack of amino acid (glycine, Gly) change in position 10

Frontiers in Oncology

The findings suggest that these patients may benefit from additional novel therapies in the conditioning regimen or post-transplant stage.

Hematology Advisor

In order to better treat patients diagnosed with acute myeloid leukemia (AML), the pathological processes and also existing subtypes of the disease must be better understood.

Medical Xpress

A new mutation was identified in 9% of relapsed cases of pediatric acute myeloid leukemia (AML) that may define a new subtype of the disease...

The ASCO Post

Scientists evaluated the potential for emvododstat to inhibit the progression of acute myeloid leukemia using several in vitro and in vivo models of the disease. 

Frontiers in Oncology

Gilteritinib may improve long-term outcomes, compared with salvage chemotherapy, in patients with R/R FLT3-mutated AML, according to updated data from the ADMIRAL trial published in Blood.

Hematology Advisor

In AML patients who were ineligible for intensive chemotherapy, the addition of the IDH1 inhibitor ivosidenib to azacitidine significantly improved survival vs azacitidine alone. 

The ASCO Post

Black AYAs with AML have shorter OS than White AYAs with AML, according to research presented at the 2021 ASH Annual Meeting.

Cancer Therapy Advisor

Dexamethasone exhibits antileukemic properties in patients who have acute myeloid leukemia and prolongs survival, according to a new study.

Oncology Times - Latest Articles

Researchers recently identified the RUNX3 gene as an oncogene in AML cells in a new study with results reported in Frontiers in Oncology.

Hematology Advisor

Researchers use trial-level and patient-level data from trials of intensive chemotherapy in patients with newly diagnosed AML to examine the relationship between CR rate and EFS with OS.

Journal of Clinical Oncology

An analysis of the ASH RC COVID-19 Registry of patients with AML, MDS, or ALL found that active disease was associated with an increased risk of developing severe COVID-19. 

Cancer Therapy Advisor

An analysis of the phase 3 ASTRAL-2 trial did not show an OS benefit with guadecitabine in patients with R/R AML, but possible benefits were seen for some subgroups. 

Hematology Advisor

This study reports diverging trends in the risk of tAML and tMDS after adoption of modern cancer therapies for specific cancers.

Scientific Reports

Scientists investigated the expression, prognostic significance, and functional role of the Receptor Activator of Nuclear Factor-κB in AML.


This research suggests that prophylactic MCF is safe and effective in pts with newly diagnosed AML undergoing induction chemotherapy.

Open Forum Infectious Diseases

Researchers conducted a classic dropout viability screen in combination with a minimal dose of either azacytidine or cytarabine to uncover targets whose depletion decreases viability...

Scientific Reports

Scientists investigate the impact of perioperative neutropenia on development of CESI and CLABSI in a large and well-defined cohort of highly vulnerable pediatric AML patients...

Frontiers in Oncology

This research suggests that the sEV-related miR-19a-3p may represent a potential therapeutic target for NPM1mut AML.

Journal of Extracellular Vesicles

Researchers found that BETi, similar to ATO + ATRA, induced differentiation and apoptosis which was TP53 independent in the NPM1c cell line OCI-AML3 and primary cells. 


source list reference

RGB(78, 191, 50)
rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb (132, 101, 173)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
RGB(171, 29, 196)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (132, 101, 173)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb (132, 101, 173)
rgb(181, 112, 164)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
rgb(245, 111, 66)
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
rgb(11, 160, 224)
rgb(66, 135, 245)
rgb(101, 11, 212)
rgb(169, 196, 201)
rgb(125, 127, 130)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
rbg(16, 162, 230)
rgb(110, 57, 65)
rgb(217, 7, 192)
rgb (247, 7, 79)
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
rgb(214, 139, 202)
rgb (132, 101, 173)
rgb(10, 191, 137)